The Efficiency and Cost Benefits of an Innovative UV-Vis Spectrophotometer

UV-Vis spectroscopy is a mature technology used to analyse, characterise, and quantify pharmaceutical and biological samples such as active pharmaceutical ingredients, DNA/RNA, and proteins for many decades. The use of UV-Vis has been limited by the workflow needed to make these measurements efficiently. The recent advances in UV-Vis spectroscopy focus on enhancing laboratory productivity, offering ease of use, and providing multiple accessories designed specifically for application needs.

Pharmaceutical and biopharmaceutical materials have become more sophisticated in life science research across fields (such as cancer research, drug development, vaccines, and quality control in regulated environments). The technology used for the analysis should evolve, too.

This webinar will highlight the benefit of the new Agilent Cary 3500 Flexible UV-Vis spectrophotometer and its capabilities in improving workflows in the pharmaceutical industry.



Geethika Weragoda
Application Scientist
Agilent Technologies, Australia


Register and watch on demand >


Industrialising High-Throughput Glycoproteomics Using AI for Clinical Use

Cancer is a leading cause of death worldwide and there is a great movement globally to develop new treatments and advance how cancer is diagnosed. Technology has been a great help, particularly in recent years, and now there’s new innovation that could take our cancer diagnosis and treatment to a new level.

According to an article published by The Guardian, doctors, scientists and researchers have built an artificial intelligence model that can accurately identify cancer in a development they say could speed up diagnosis of the disease and fast-track patients to treatment. This is but one of many new developments that include AI technology in cancer diagnosis as well as treatment.

In this webinar, we learn the predictive powers of artificial intelligence combined with cutting-edge mass spectrometry to discover clinically relevant biomarkers that can only be revealed by high-resolution analysis of the glycoproteome. This presentation is for all who are interested to learn more about the real-world clinical application of glycoproteomics on cancer diagnosis.



Dr. Low Ley Hian
Director of Development
InterVenn Biosciences


Register and watch on demand >